Ph.D., Founder & Chief Strategy Officer, Atreca, Inc.
Biography
Dr. Serafini is one of the three principal founders of Atreca and was CEO from the company’s inception in 2010 until 2018. In his role as Chief Strategy Officer, Dr. Serafini is responsible directly for research, preclinical development, technology, and intellectual property. Before co-founding Atreca, he was Chief Scientific Officer of Nuon Therapeutics, a development-stage biotechnology company. Previously, Dr. Serafini was a founder of Renovis, a public biotechnology company, where he served as an executive officer in multiple technical and business management roles, including leading the research and M&A functions. Prior to founding Renovis, Dr. Serafini was an award-winning faculty member in the Department of Molecular and Cell Biology at the University of California, Berkeley, where he established the university’s Functional Genomics Laboratory.
Talk
Emerging Therapeutics Showcase:
Atreca, Inc.
Atreca is a clinical-stage biotechnology company inverting the traditional approach to cancer drug discovery. Atreca’s unique platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors.
The Next Frontier of Therapeutic Antibodies
Addressing unmet medical need in oncology and identifying novel targets at a more rapid pace.
Session Abstract – PMWC 2023 Silicon Valley
Showcase Track S1 - January 27 9.45 A.M.-1.45 P.M.
The PMWC 2023 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy
